 | • レポートコード：MRC2Q12-18956 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、血液疾患用補完薬のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 血液疾患用補完薬のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 血液疾患用補完薬の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 血液疾患用補完薬のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの血液疾患用補完薬の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の血液疾患用補完薬の売上および2028年までの予測に焦点を当てています。 血液疾患用補完薬のグローバル主要企業には、Amyndas、Apellis、Novartis、Roche、Regeneron、Amgen、Samsung Bioepis、Alnylam、Akari Therapeutics、UCBなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 血液疾患用補完薬市場は、タイプとアプリケーションによって区分されます。世界の血液疾患用補完薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 ペプチド、抗体、その他 【アプリケーション別セグメント】 病院、診療所、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 血液疾患用補完薬製品概要 - タイプ別市場（ペプチド、抗体、その他） - アプリケーション別市場（病院、診療所、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の血液疾患用補完薬販売量予測2017-2028 - 世界の血液疾患用補完薬売上予測2017-2028 - 血液疾患用補完薬の地域別販売量 - 血液疾患用補完薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別血液疾患用補完薬販売量 - 主要メーカー別血液疾患用補完薬売上 - 主要メーカー別血液疾患用補完薬価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（ペプチド、抗体、その他） - 血液疾患用補完薬のタイプ別販売量 - 血液疾患用補完薬のタイプ別売上 - 血液疾患用補完薬のタイプ別価格 ・アプリケーション別市場規模（病院、診療所、その他） - 血液疾患用補完薬のアプリケーション別販売量 - 血液疾患用補完薬のアプリケーション別売上 - 血液疾患用補完薬のアプリケーション別価格 ・北米市場 - 北米の血液疾患用補完薬市場規模（タイプ別、アプリケーション別） - 主要国別の血液疾患用補完薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの血液疾患用補完薬市場規模（タイプ別、アプリケーション別） - 主要国別の血液疾患用補完薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の血液疾患用補完薬市場規模（タイプ別、アプリケーション別） - 主要国別の血液疾患用補完薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の血液疾患用補完薬市場規模（タイプ別、アプリケーション別） - 主要国別の血液疾患用補完薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの血液疾患用補完薬市場規模（タイプ別、アプリケーション別） - 主要国別の血液疾患用補完薬市場規模（トルコ、サウジアラビア） ・企業情報 Amyndas、Apellis、Novartis、Roche、Regeneron、Amgen、Samsung Bioepis、Alnylam、Akari Therapeutics、UCB ・産業チェーン及び販売チャネル分析 - 血液疾患用補完薬の産業チェーン分析 - 血液疾患用補完薬の原材料 - 血液疾患用補完薬の生産プロセス - 血液疾患用補完薬の販売及びマーケティング - 血液疾患用補完薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 血液疾患用補完薬の産業動向 - 血液疾患用補完薬のマーケットドライバー - 血液疾患用補完薬の課題 - 血液疾患用補完薬の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Complement Drug for Blood Disease estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Complement Drug for Blood Disease is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Complement Drug for Blood Disease is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Complement Drug for Blood Disease is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Complement Drug for Blood Disease include Amyndas, Apellis, Novartis, Roche, Regeneron, Amgen, Samsung Bioepis, Alnylam and Akari Therapeutics, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Complement Drug for Blood Disease companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Complement Drug for Blood Disease market. Further, it explains the major drivers and regional dynamics of the global Complement Drug for Blood Disease market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Amyndas
Apellis
Novartis
Roche
Regeneron
Amgen
Samsung Bioepis
Alnylam
Akari Therapeutics
UCB
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Complement Drug for Blood Disease Segment by Type
Peptides
Antibodies
Others
Complement Drug for Blood Disease Segment by Application
Hospital
Clinic
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Complement Drug for Blood Disease market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Complement Drug for Blood Disease market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Complement Drug for Blood Disease, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Complement Drug for Blood Disease, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Complement Drug for Blood Disease revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Complement Drug for Blood Disease market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Complement Drug for Blood Disease revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Amyndas, Apellis, Novartis, Roche, Regeneron, Amgen, Samsung Bioepis, Alnylam and Akari Therapeutics, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Complement Drug for Blood Disease in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Complement Drug for Blood Disease companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Complement Drug for Blood Disease revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Complement Drug for Blood Disease Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Peptides
1.2.3 Antibodies
1.2.4 Others
1.3 Market by Application
1.3.1 Global Complement Drug for Blood Disease Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Complement Drug for Blood Disease Market Perspective (2017-2028)
2.2 Complement Drug for Blood Disease Growth Trends by Region
2.2.1 Complement Drug for Blood Disease Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Complement Drug for Blood Disease Historic Market Size by Region (2017-2022)
2.2.3 Complement Drug for Blood Disease Forecasted Market Size by Region (2023-2028)
2.3 Complement Drug for Blood Disease Market Dynamics
2.3.1 Complement Drug for Blood Disease Industry Trends
2.3.2 Complement Drug for Blood Disease Market Drivers
2.3.3 Complement Drug for Blood Disease Market Challenges
2.3.4 Complement Drug for Blood Disease Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Complement Drug for Blood Disease Players by Revenue
3.1.1 Global Top Complement Drug for Blood Disease Players by Revenue (2017-2022)
3.1.2 Global Complement Drug for Blood Disease Revenue Market Share by Players (2017-2022)
3.2 Global Complement Drug for Blood Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Complement Drug for Blood Disease Revenue
3.4 Global Complement Drug for Blood Disease Market Concentration Ratio
3.4.1 Global Complement Drug for Blood Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Complement Drug for Blood Disease Revenue in 2021
3.5 Complement Drug for Blood Disease Key Players Head office and Area Served
3.6 Key Players Complement Drug for Blood Disease Product Solution and Service
3.7 Date of Enter into Complement Drug for Blood Disease Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Complement Drug for Blood Disease Breakdown Data by Type
4.1 Global Complement Drug for Blood Disease Historic Market Size by Type (2017-2022)
4.2 Global Complement Drug for Blood Disease Forecasted Market Size by Type (2023-2028)
5 Complement Drug for Blood Disease Breakdown Data by Application
5.1 Global Complement Drug for Blood Disease Historic Market Size by Application (2017-2022)
5.2 Global Complement Drug for Blood Disease Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Complement Drug for Blood Disease Market Size (2017-2028)
6.2 North America Complement Drug for Blood Disease Market Size by Type
6.2.1 North America Complement Drug for Blood Disease Market Size by Type (2017-2022)
6.2.2 North America Complement Drug for Blood Disease Market Size by Type (2023-2028)
6.2.3 North America Complement Drug for Blood Disease Market Share by Type (2017-2028)
6.3 North America Complement Drug for Blood Disease Market Size by Application
6.3.1 North America Complement Drug for Blood Disease Market Size by Application (2017-2022)
6.3.2 North America Complement Drug for Blood Disease Market Size by Application (2023-2028)
6.3.3 North America Complement Drug for Blood Disease Market Share by Application (2017-2028)
6.4 North America Complement Drug for Blood Disease Market Size by Country
6.4.1 North America Complement Drug for Blood Disease Market Size by Country (2017-2022)
6.4.2 North America Complement Drug for Blood Disease Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Complement Drug for Blood Disease Market Size (2017-2028)
7.2 Europe Complement Drug for Blood Disease Market Size by Type
7.2.1 Europe Complement Drug for Blood Disease Market Size by Type (2017-2022)
7.2.2 Europe Complement Drug for Blood Disease Market Size by Type (2023-2028)
7.2.3 Europe Complement Drug for Blood Disease Market Share by Type (2017-2028)
7.3 Europe Complement Drug for Blood Disease Market Size by Application
7.3.1 Europe Complement Drug for Blood Disease Market Size by Application (2017-2022)
7.3.2 Europe Complement Drug for Blood Disease Market Size by Application (2023-2028)
7.3.3 Europe Complement Drug for Blood Disease Market Share by Application (2017-2028)
7.4 Europe Complement Drug for Blood Disease Market Size by Country
7.4.1 Europe Complement Drug for Blood Disease Market Size by Country (2017-2022)
7.4.2 Europe Complement Drug for Blood Disease Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Complement Drug for Blood Disease Market Size (2017-2028)
8.2 Asia-Pacific Complement Drug for Blood Disease Market Size by Type
8.2.1 Asia-Pacific Complement Drug for Blood Disease Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Complement Drug for Blood Disease Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Complement Drug for Blood Disease Market Share by Type (2017-2028)
8.3 Asia-Pacific Complement Drug for Blood Disease Market Size by Application
8.3.1 Asia-Pacific Complement Drug for Blood Disease Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Complement Drug for Blood Disease Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Complement Drug for Blood Disease Market Share by Application (2017-2028)
8.4 Asia-Pacific Complement Drug for Blood Disease Market Size by Region
8.4.1 Asia-Pacific Complement Drug for Blood Disease Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Complement Drug for Blood Disease Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Complement Drug for Blood Disease Market Size (2017-2028)
9.2 Latin America Complement Drug for Blood Disease Market Size by Type
9.2.1 Latin America Complement Drug for Blood Disease Market Size by Type (2017-2022)
9.2.2 Latin America Complement Drug for Blood Disease Market Size by Type (2023-2028)
9.2.3 Latin America Complement Drug for Blood Disease Market Share by Type (2017-2028)
9.3 Latin America Complement Drug for Blood Disease Market Size by Application
9.3.1 Latin America Complement Drug for Blood Disease Market Size by Application (2017-2022)
9.3.2 Latin America Complement Drug for Blood Disease Market Size by Application (2023-2028)
9.3.3 Latin America Complement Drug for Blood Disease Market Share by Application (2017-2028)
9.4 Latin America Complement Drug for Blood Disease Market Size by Country
9.4.1 Latin America Complement Drug for Blood Disease Market Size by Country (2017-2022)
9.4.2 Latin America Complement Drug for Blood Disease Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Complement Drug for Blood Disease Market Size (2017-2028)
10.2 Middle East & Africa Complement Drug for Blood Disease Market Size by Type
10.2.1 Middle East & Africa Complement Drug for Blood Disease Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Complement Drug for Blood Disease Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Complement Drug for Blood Disease Market Share by Type (2017-2028)
10.3 Middle East & Africa Complement Drug for Blood Disease Market Size by Application
10.3.1 Middle East & Africa Complement Drug for Blood Disease Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Complement Drug for Blood Disease Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Complement Drug for Blood Disease Market Share by Application (2017-2028)
10.4 Middle East & Africa Complement Drug for Blood Disease Market Size by Country
10.4.1 Middle East & Africa Complement Drug for Blood Disease Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Complement Drug for Blood Disease Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Amyndas
11.1.1 Amyndas Company Details
11.1.2 Amyndas Business Overview
11.1.3 Amyndas Complement Drug for Blood Disease Introduction
11.1.4 Amyndas Revenue in Complement Drug for Blood Disease Business (2017-2022)
11.1.5 Amyndas Recent Developments
11.2 Apellis
11.2.1 Apellis Company Details
11.2.2 Apellis Business Overview
11.2.3 Apellis Complement Drug for Blood Disease Introduction
11.2.4 Apellis Revenue in Complement Drug for Blood Disease Business (2017-2022)
11.2.5 Apellis Recent Developments
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Complement Drug for Blood Disease Introduction
11.3.4 Novartis Revenue in Complement Drug for Blood Disease Business (2017-2022)
11.3.5 Novartis Recent Developments
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Complement Drug for Blood Disease Introduction
11.4.4 Roche Revenue in Complement Drug for Blood Disease Business (2017-2022)
11.4.5 Roche Recent Developments
11.5 Regeneron
11.5.1 Regeneron Company Details
11.5.2 Regeneron Business Overview
11.5.3 Regeneron Complement Drug for Blood Disease Introduction
11.5.4 Regeneron Revenue in Complement Drug for Blood Disease Business (2017-2022)
11.5.5 Regeneron Recent Developments
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Complement Drug for Blood Disease Introduction
11.6.4 Amgen Revenue in Complement Drug for Blood Disease Business (2017-2022)
11.6.5 Amgen Recent Developments
11.7 Samsung Bioepis
11.7.1 Samsung Bioepis Company Details
11.7.2 Samsung Bioepis Business Overview
11.7.3 Samsung Bioepis Complement Drug for Blood Disease Introduction
11.7.4 Samsung Bioepis Revenue in Complement Drug for Blood Disease Business (2017-2022)
11.7.5 Samsung Bioepis Recent Developments
11.8 Alnylam
11.8.1 Alnylam Company Details
11.8.2 Alnylam Business Overview
11.8.3 Alnylam Complement Drug for Blood Disease Introduction
11.8.4 Alnylam Revenue in Complement Drug for Blood Disease Business (2017-2022)
11.8.5 Alnylam Recent Developments
11.9 Akari Therapeutics
11.9.1 Akari Therapeutics Company Details
11.9.2 Akari Therapeutics Business Overview
11.9.3 Akari Therapeutics Complement Drug for Blood Disease Introduction
11.9.4 Akari Therapeutics Revenue in Complement Drug for Blood Disease Business (2017-2022)
11.9.5 Akari Therapeutics Recent Developments
11.10 UCB
11.10.1 UCB Company Details
11.10.2 UCB Business Overview
11.10.3 UCB Complement Drug for Blood Disease Introduction
11.10.4 UCB Revenue in Complement Drug for Blood Disease Business (2017-2022)
11.10.5 UCB Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer